We are headquartered at 1104 West Broad Street #1029, Falls Church, Virginia 22046.
Retension Pharmaceuticals, Inc. was incorporated in Delaware on July 26, 2023.
Retension’s independent registered public accounting firm is Wolf & Company, P.C.
Retension’s corporate counsel is DLA Piper LLP (US).
You can reach the Retension Investor Relations team via e-mail at investors@retensionpharmaceuticals.com.
If you are a registered Retension shareholder, please contact our transfer agent: Computershare Trust Company, N.A., 150 Royall Street, Suite 101, Canton, MA 02021. Website: https://www.computershare.com/investor
You can visit www.retensionpharmaceuticals.com for more information.
You can find news releases in the News & Events section and financial reports in the Financials & Filings section within this investor relations website.
SEC documents are available in the SEC Filings section of this investor relations website.
Retension Pharmaceuticals is listed its common stock on the Nasdaq Capital Market under the symbol “RTSN”.